Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Gossamer Bio Q4 EPS $(0.21), Inline; Cash, Cash Equivalents And Marketable Securities Of $296.4M Is Expected To Provide Cash Runway Into The First Half Of 2026

Author: Benzinga Newsdesk | March 05, 2024 08:36am
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.21) per share which met the analyst consensus estimate. This is a 64.41 percent increase over losses of $(0.59) per share from the same period last year.

Posted In: GOSS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist